Exploring the Diagnostic Value of High-Frequency Ultrasound Technology for Subcutaneous Lipohypertrophy in Diabetes Patients Receiving Insulin Injections
Zhan-He Sun,Cheng-Hong Yu,Xin Wang
DOI: https://doi.org/10.2147/dmso.s443737
2024-03-20
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Zhan-He Sun, &ast Cheng-Hong Yu, &ast Xin Wang Department of Ultrasound, Tongxiang First People's Hospital, Tongxiang, Zhejiang Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xin Wang, Email Objective: This study aims to investigate the clinical application value of high-frequency ultrasound technology in diagnosing subcutaneous lipohypertrophy at insulin injection sites in diabetes patients. Methods: All diabetes patients treated in our hospital from January 2022 to January 2023 were selected as the study subjects. The incidence of subcutaneous lipohypertrophy was calculated at the end of the study period. All patients were screened, and those meeting the inclusion criteria were registered, and basic data were collected. Patients were screened for subcutaneous lipohypertrophy using conventional clinical examination (control group) and high-frequency ultrasound technology (study group). Results: The study found that the incidence of subcutaneous lipohypertrophy in diabetes patients receiving insulin injections in our hospital from January 2022 to January 2023 was 80.99%. The average longitudinal diameter of subcutaneous lipohypertrophy in these patients was 11.66 (7.56, 21.44) mm, the transverse diameter was 12.04 (8.96, 18.29) mm, depth was (5.62± 2.17) mm, and the area was 188.79 (76.85, 331.78) mm2. The clinical detection rate in the study group was higher than that in the control group (P< 0.05). The quantity of detected sites was greater in the study group compared to the control group (P< 0.05). Conclusion: The incidence of subcutaneous lipohypertrophy in diabetes patients receiving insulin injections is relatively high clinically, and high-frequency ultrasound technology demonstrates significant potential in diagnosis. By providing high-resolution imaging and quantitative data, it effectively improves the clinical detection rate and clarifies symptoms. This technology is likely to become an important auxiliary tool in future diabetes treatment, providing more precise treatment plans for patients. Keywords: high-frequency ultrasound technology, diabetes, insulin injection, subcutaneous lipohypertrophy, diagnostic value Diabetes is a chronic metabolic disorder characterized by abnormal elevation of blood glucose levels due to insufficient insulin secretion or impaired insulin effectiveness. 1 Insulin, a hormone secreted by the pancreas, plays a crucial role in aiding cells in the body to absorb glucose, thereby maintaining normal blood glucose levels. 2 Insulin injection is a primary method of diabetes treatment, but subcutaneous lipohypertrophy has become a common yet challenging phenomenon during insulin injection therapy. 3 This hypertrophy not only affects the absorption and efficacy of insulin but may also lead to issues such as pain and bruising at the injection site, impacting the effectiveness of treatment. 4 High-frequency ultrasound technology not only provides visual imaging but also enables quantitative analysis. It utilizes the propagation characteristics of high-frequency sound waves in tissues to offer clear and real-time imaging of subcutaneous tissues. 5 Its advantages, including radiation-free and non-invasive features, allow for more frequent monitoring, providing timely feedback for treatment. Through high-resolution imaging of injection sites, healthcare professionals can visually observe the hypertrophy of the fat layer, offering a basis for treatment adjustments. 6 Given its potential value in detecting subcutaneous lipohypertrophy in diabetes patients, this article explores the possible significance and future applications of high-frequency ultrasound technology in diagnosing subcutaneous lipohypertrophy in diabetes patients receiving insulin injections. Real-time, high-definition imaging of injection sites holds the promise of a more comprehensive and accurate understanding of dynamic changes in subcutaneous tissues, providing robust support for the development of personalized treatment plans. In the face of the complex challenges in diabetes management, high-frequency ultrasound technology may emerge as a groundbreaking diagnostic tool, contributing positively to enhancing treatment outcomes and improving the quality of life for patients. This study aims to investigate the clinical application value of high-frequency ultrasound technology in diagnosing subcutaneous lipohypertrophy at insulin injection sites in diabetes patients. The primary endpoint of this study is to assess the incidence of subcutaneous lipohypertrophy in diabetes patients receiving insulin injections. The secondary endpoints include evaluating the size and cha -Abstract Truncated-
endocrinology & metabolism